Publication

The ECHELON-2 trial: results of a randomized, double-blind, active-controlled phase 3 Study of brentuximab vedotin and CHP (A plus CHP) versus CHOP in the frontline treatment of patients with CD30+peripheral T-Cell lymphomas

Horwitz, M
; 
O'Connor, A
; 
Pro, B
; 
Illidge, Timothy M
; 
Fanale, A
; 
Advani, H
; 
Bartlett, L
; 
Christensen, H
; 
Morschhauser, F
; 
Domingo-Domenech, E
... show 10 more
Citations
Altmetric:
Abstract
Authors
Horwitz, M
O'Connor, A
Pro, B
Illidge, Timothy M
Fanale, A
Advani, H
Bartlett, L
Christensen, H
Morschhauser, F
Domingo-Domenech, E
Rossi, G
Kim, S
Feldman, A
Lennard, A
Belada, D
Illes, A
Tobinai, K
Tsukasaki, K
Yeh, P
Shustov, R
Huttmann, A
Savage, J
Yuen, S
Zinzani, L
Hua, W
Little, M
Rao, B
Woolery, J
Manley, T
Trumper, L
Affiliation
Department of Hematology and Transplantation, Hôpital Saint Louis, Colombes, France
Description
Date
2018
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Horwitz S, O'Connor O, Pro B, Illidge TM, Fanale M, Advani R, et al. The ECHELON-2 trial: results of a randomized, double-blind, active-controlled phase 3 Study of brentuximab vedotin and CHP (A plus CHP) versus CHOP in the frontline treatment of patients with CD30+peripheral T-Cell lymphomass. Blood. 2018;132.#10.1182/blood-2018-99-110563
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/621665
Embedded videos